Riemann–Hilbert problems, Toeplitz operators and Q-classes

We generalize the notion of Q-classes C(Q1,Q2) , which was introduced in the context of Wiener–Hopf factorization, by considering very general 2 × 2 matrix functions Q1, Q2. This allows us to use a mainly algebraic approach to obtain several equivalent representations for each class, to study the intersections of Q-classes and to explore their close connection with certain non-linear scalar equations. The results are applied to various factorization problems and to the study of Toeplitz operators with symbol in a Q-class. We conclude with a group theoretic interpretation of some of the main results.Fundação para a Ciência e a Tecnologia (FCT/Portugal), through Project PTDC/MAT/121837/2010 and Project Est- C/MAT/UI0013/2011. The first author was also supported by the Center for Mathematical Analysis, Geometry, and Dynamical Systems and the second author was also supported by the Centre of Mathematics of the University of Minho through the FEDER Funds Programa Operacional Factores de Competitividade COMPET

Expression of IL-20 in synovium and lesional skin of patients with psoriatic arthritis: differential response to alefacept treatment

Introduction: Psoriatic arthritis (PsA) is an inflammatory joint disease associated with psoriasis. Alefacept (a lymphocyte function-associated antigen (LFA)-3 Ig fusion protein that binds to CD2 and functions as an antagonist to T-cell activation) has been shown to result in improvement in psoriasis but has limited effectiveness in PsA. Interleukin-20 (IL-20) is a key proinflammatory cytokine involved in the pathogenesis of psoriasis. The effects of alefacept treatment on IL-20 expression in the synovium of patients with psoriasis and PsA are currently unknown.Methods: Eleven patients with active PsA and chronic plaque psoriasis were treated with alefacept (7.5 mg per week for 12 weeks) in an open-label study. Skin biopsies were taken before and after 1 and 6 weeks, whereas synovial biopsies were obtained before and 4 and 12 weeks after treatment. Synovial biopsies from patients with rheumatoid arthritis (RA) (n = 10) were used as disease controls. Immunohistochemical analysis was performed to detect IL-20 expression, and stained synovial tissue sections were evaluated with digital image analysis. Double staining was performed with IL-20 and CD68 (macrophages), and conversely with CD55 (fibroblast-like synoviocytes, FLSs) to determine the phenotype of IL-20-positive cells in PsA synovium. IL-20 expression in skin sections (n = 6) was analyzed semiquantitatively.Results: IL-20 was abundantly expressed in both PsA and RA synovial tissues. In inflamed PsA synovium, CD68+ macrophages and CD55+ FLSs coexpressed IL-20, and its expression correlated with the numbers of FLSs. IL-20 expression in lesional skin of PsA patients decreased significantly (P = 0.04) 6 weeks after treatment and correlated positively with the Psoriasis Area and Severity Index (PASI). IL-20 expression in PsA synovium was not affected by alefacept.Conclusions: Conceivably, the relatively limited effectiveness of alefacept in PsA patients (compared with anti-tumor necrosis factor (TNF) therapy) might be explained in part by persistent FLS-derived IL-20 expression

Inhibition of contact sensitizer-induced migration of human Langerhans cells by matrix metalloproteinase inhibitors

Emigration of Langerhans cells (LC) from the epidermis upon exposure to contact sensitizers is regarded as an essential event in the development of contact sensitization. Since migration of several types of cells depends on the activity of matrix metalloproteinases (MMPs), in the present study we tested whether MMP inhibitors (BB94, BB2116 and CT1166) can prevent the emigration of LC in cultured skin explants, which were exposed to a contact sensitizer (NiSO4). Epicutaneous application of NiSO4 significantly reduced the number of LC within the epidermis and the remaining LC were localized along the epidermal-dermal junction indicating the emigration of LC. In the presence of each of the MMP inhibitors tested, NiSO4-induced migration of LC was strongly decreased. Since after the epicutaneous application of contact sensitizer, its presentation by skin LC is essential for the development of contact sensitization instead of the development of antigen-specific tolerance, our results suggest that the use of MMP inhibitors may be beneficial for the prevention of contact sensitization of the hos

Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis

The aim of this study was to provide more insight into the question as to why blockade of CCR1, CCR2, and CCR5 may have failed in clinical trials in rheumatoid arthritis (RA) patients, using an in vitro monocyte migration system model. Monocytes from healthy donors (HD; n = 8) or from RA patients (for CCR2 and CCR5 antibody n = 8; for CCR1 blockade n = 13) were isolated from peripheral blood and pre-incubated with different concentrations of either anti-CCR1, anti-CCR2, or anti-CCR5 blocking antibodies (or medium or isotype controls). In addition, a small molecule CCR1 antagonist (BX471) was tested. Chemotaxis was induced by CCL2/MCP-1 (CCR2 ligand), CCL5/RANTES (CCR1 and CCR5 ligand), or by a mix of 5 RA synovial fluids (SFs), and cellular responses compared to chemotaxis in the presence of medium alone. Anti-CCR2 antibody treatment blocked CCL2/MCP-1-induced chemotaxis of both HD and RA monocytes compared to isotype control. Similarly, anti-CCR5 antibody treatment blocked CCL5/RANTES-induced chemotaxis of RA monocytes. While neither CCR2 nor CCR5 blocking antibodies were able to inhibit SF-induced monocyte chemotaxis, even when both receptors were blocked simultaneously, both anti-CCR1 antibodies and the CCR1 antagonist were able to inhibit SF-induced monocyte chemotaxis. The RA synovial compartment contains several ligands for CCR1, CCR2, and CCR5 as well as other chemokines and receptors involved in monocyte recruitment to the site of inflammation. The results suggest that CCR2 and CCR5 are not critical for the migration of monocytes towards the synovial compartment in RA. In contrast, blockade of CCR1 may be effective. Conceivably, CCR1 blockade failed in clinical trials, not because CCR1 is not a good target, but because very high levels of receptor occupancy at all times may be needed to inhibit monocyte migration in viv